David Hayes

David Hayes

Auto-generated profile, based on publicly available information

David Hayes

International Solidarity of Scientists, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Analytical Biochemistry
Verified
Journal Article
Closed access
RWRobert T. Wright
Robert T. Wright
DHDavid B. Hayes
David B. Hayes
WSWalter F. Stafford
Walter F. Stafford
PSPeter J. Sherwood
Peter J. Sherwood
JCJohn J. Correia
John J. Correia

16 February 2016 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Open access
PDF file
APAnil K. Padyana
Anil K. Padyana
BVBhamini Vaidialingam
Bhamini Vaidialingam
DHDavid B. Hayes
David B. Hayes
PGPriyanka Gupta
Priyanka Gupta
MFMichael Franti
Michael Franti
NFNeil A. Farrow
Neil A. Farrow
Members of the TGF-β family of proteins are believed to play critical roles in cellular signaling processes such as those involved in muscle differentiation. The extent to which individual family members have been characterized and linked to biological function varies greatly. The role of myostatin, also known as growth differentiation factor 8 (GDF8), as an inhibitor of muscle differentiation is well understood through genetic linkages. In contrast, the role of growth differentiation factor 11 (GDF11) is much less well understood. In humans, the mature forms of GDF11 and myostatin are over 94% identical. In order to understand the role that the small differences in sequence may play in the differential signaling of these molecules, the crystal structure of GDF11 was determined to a resolution of 1.50 Å. A comparison of the GDF11 structure with those of other family members reveals that the canonical TGF-β domain fold is conserved. A detailed structural comparison of GDF11 and myostatin shows that several of the differences between these proteins are likely to be localized at interfaces that are critical for the interaction with downstream receptors and inhibitors.

15 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
NHNatalia G. Herrera
Natalia G. Herrera
NMNicholas C. Morano
Nicholas C. Morano
ACAlev Celikgil
Alev Celikgil
GGGeorge I. Georgiev
George I. Georgiev
RMRyan J. Malonis
Ryan J. Malonis
SASteven C Almo
Steven C Almo
Coronavirus disease 2019 ( COVID-19 ) is a global health crisis caused by the novel severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), and there is a critical need to produce large quantities of high-quality SARS-CoV-2 Spike ( S ) protein for use in both clinical and basic science settings. To address this need, we have evaluated the expression and purification of two previously reported S protein constructs in Expi293F ™ and ExpiCHO-S ™ cells, two different cell lines selected for increased expression of secreted glycoproteins. We show that ExpiCHO-S ™ cells produce enhanced yields of both SARS-CoV-2 S proteins. Biochemical, biophysical, and structural ( cryo-EM ) characterization of the SARS-CoV-2 S proteins produced in both cell lines demonstrate that the reported purification strategy yields high quality S protein (non-aggregated, uniform material with appropriate biochemical and biophysical properties). Importantly, we show that multiple preparations of these two recombinant S proteins from either cell line exhibit identical behavior in two different serology assays. We also evaluate the specificity of S protein-mediated host cell binding by examining interactions with proposed binding partners in the human secretome. In addition, the antigenicity of these proteins is demonstrated by standard ELISAs, and in a flexible protein microarray format. Collectively, we establish an array of metrics for ensuring the production of high-quality S protein to support clinical, biological, biochemical, structural and mechanistic studies to combat the global pandemic caused by SARS-CoV-2.


7 November 2018 in mAbs
Verified
Journal Article
Open access
CZChao Zheng
Chao Zheng
JTJoshuaine Toth
Joshuaine Toth
TBTammy Bigwarfe
Tammy Bigwarfe
MMMargit MacDougall
Margit MacDougall
KJKavita Jerath
Kavita Jerath
RKRachel Kroe-Barrett
Rachel Kroe-Barrett
Ang1 is a soluble ligand to receptor Tie2, and increasing the circulating Ang1 level may improve vascular stabilization under certain disease conditions. Here, we found that the circulating Ang1 level was significantly increased in cynomolgus monkeys treated with non-neutralizing anti-Ang1 antibodies. Improving the antibodies’ pharmacokinetic properties by IgG Fc mutations further increased the circulating Ang1 level. However, the mutations decreased the thermal stability of the molecules, which may limit their use as therapeutic antibodies. Nevertheless, we showed that non-neutralizing antibodies may have therapeutic potential by increasing the level of a target molecule in the circulation.